Pluristem Therapeutics, Inc. (PSTI) Licensee Gets Regulatory Approval to Begin Phase I Study of PLX-PAD Cells
Pluristem Therapeutics is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ishemic diseases. The cells are grown using the company's proprietary 3D micro-environmental technology. The company today announced that following favorable pre-clinical studies, biotechnology firm United Therapeutics Corp. received approval to perform a human Phase 1 study in Australia using Pluristem's PLX-PAD cells in patients that have been diagnosed with pulmonary arterial hypertension (PAH). This disease is characterized by abnormally high…